Compare ADMA Biologics Inc (ADMA) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Tripadvisor Inc Common Stock — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Tripadvisor Inc Common Stock trades at $13.02 (market cap $1.66B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Tripadvisor Inc Common Stock is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | TRIP | |
|---|---|---|
Market Cap | $2.13B | $1.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $19.14 |
52-Week Low | $7.60 | $9.24 |
Enterprise Value | $2.20B | $1.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
TRIP trades at $13.72, down 3.99% today, with a consensus price target of $13.87. The stock shows a bullish technical trend and recently announced the $700 million sale of TheFork to American Express. Despite mixed quarterly earnings, 2025 revenue grew to $1.89 billion with a net income margin of 0.99%. Analyst sentiment is mixed, with 60.72% holding and 23.21% recommending buy.
The outlook is cautiously optimistic. The sale of TheFork provides cash but removes a growth segment. Earnings volatility and competitive pressures in online travel pose risks. Upside depends on execution in core segments and macroeconomic stability. Current valuation metrics suggest the stock is fairly priced relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
